Skip to main content
Erschienen in: Pathology & Oncology Research 2/2013

01.04.2013 | Research

The Expression of Non-Mast Histamine in Tumor Associated Microvessels in Human Colorectal Cancers

verfasst von: Jing Cui, Gang Xu, Jinzhong Liu, Zhigang Pang, Jon Florholmen, Guanglin Cui

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Angiogenesis is essential for the growth, expansion and metastasis of human colorectal cancers (CRCs). Histamine produced by mast cells is a potent proangiogenic factor. However, the significance of non-mast cell expressing histamine in the tumor microenvironment remains unknown. In this study, we evaluated the histamine positive microvessels with the specific marker for biosynthesis of histamine L-histidine decarboxylase (HDC) in the CRC tumor microenvironment. The relationship between HDC positive microvessel density (HDC-MVD) and clinical pathological parameters was assessed. The results revealed that HDC-MVD in the tumor microenvironment of CRCs was significantly increased as compared with the controls. CRC patients with lymph node invasion had a particularly higher density of HDC-MVD than those without. The density of HDC-MVD accounted for ~79 % of CD34 positive MVD in CRCs and double IHC analysis demonstrated that these HDC positive microvessels were mostly CD34 positive microvessels and with a high proliferative activity. Our results suggest that histamine expressed in microvessels could be an additional cellular source and involved in the cancer invasion through promoting angiogenesis in human CRCs.
Literatur
1.
Zurück zum Zitat Timar J, Csuka O, Orosz Z, Jeney A, Kopper L (2001) Molecular pathology of tumor metastasis. I. Predictive pathology. Pathol Oncol Res POR 7:217–230CrossRef Timar J, Csuka O, Orosz Z, Jeney A, Kopper L (2001) Molecular pathology of tumor metastasis. I. Predictive pathology. Pathol Oncol Res POR 7:217–230CrossRef
2.
Zurück zum Zitat Hubbard J, Grothey A (2010) Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 22:374–380PubMedCrossRef Hubbard J, Grothey A (2010) Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 22:374–380PubMedCrossRef
4.
Zurück zum Zitat Habibollahi P, Jamshidiha M, Daryani NE, Jahanzad I, Ghahremani MH et al (2010) Correlation between inducible nitric oxide synthase and cyclooxygenase-2 expression in human colorectal adenocarcinoma: a cross-sectional study. Pathol Oncol Res POR 16:327–335CrossRef Habibollahi P, Jamshidiha M, Daryani NE, Jahanzad I, Ghahremani MH et al (2010) Correlation between inducible nitric oxide synthase and cyclooxygenase-2 expression in human colorectal adenocarcinoma: a cross-sectional study. Pathol Oncol Res POR 16:327–335CrossRef
5.
Zurück zum Zitat Jutel M, Blaser K, Akdis CA (2005) Histamine in allergic inflammation and immune modulation. Int Arch Allergy Immunol 137:82–92PubMedCrossRef Jutel M, Blaser K, Akdis CA (2005) Histamine in allergic inflammation and immune modulation. Int Arch Allergy Immunol 137:82–92PubMedCrossRef
6.
Zurück zum Zitat Watanabe T, Ohtsu H (2002) L-histidine decarboxylase as a probe in studies on histamine. Chem Rec 2:369–376PubMedCrossRef Watanabe T, Ohtsu H (2002) L-histidine decarboxylase as a probe in studies on histamine. Chem Rec 2:369–376PubMedCrossRef
7.
Zurück zum Zitat Natori T, Sata M, Nagai R, Makuuchi M (2005) Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother 59:56–60PubMedCrossRef Natori T, Sata M, Nagai R, Makuuchi M (2005) Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother 59:56–60PubMedCrossRef
8.
Zurück zum Zitat Tomita K, Izumi K, Okabe S (2003) Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci 93:321–330PubMedCrossRef Tomita K, Izumi K, Okabe S (2003) Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci 93:321–330PubMedCrossRef
9.
Zurück zum Zitat Nielsen HJ, Hammer JH, Moesgaard F, Kehlet H (1991) Possible role of histamine-2 receptor antagonists for adjuvant treatment in colorectal cancer. Clinical review. Eur J Surg 157:437–441PubMed Nielsen HJ, Hammer JH, Moesgaard F, Kehlet H (1991) Possible role of histamine-2 receptor antagonists for adjuvant treatment in colorectal cancer. Clinical review. Eur J Surg 157:437–441PubMed
10.
Zurück zum Zitat Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H (2002) Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 89:1416–1422PubMedCrossRef Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H (2002) Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 89:1416–1422PubMedCrossRef
11.
Zurück zum Zitat Malaviya R, Uckun FM (2000) Histamine as an autocrine regulator of leukemic cell proliferation. Leuk Lymphoma 36:367–373PubMedCrossRef Malaviya R, Uckun FM (2000) Histamine as an autocrine regulator of leukemic cell proliferation. Leuk Lymphoma 36:367–373PubMedCrossRef
12.
Zurück zum Zitat Bowrey PF, King J, Magarey C, Schwartz P, Marr P et al (2000) Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? Br J Cancer 82:167–170PubMedCrossRef Bowrey PF, King J, Magarey C, Schwartz P, Marr P et al (2000) Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? Br J Cancer 82:167–170PubMedCrossRef
13.
Zurück zum Zitat Watson SA, Wilkinson LJ, Robertson JF, Hardcastle JD (1993) Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut 34:1091–1096PubMedCrossRef Watson SA, Wilkinson LJ, Robertson JF, Hardcastle JD (1993) Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut 34:1091–1096PubMedCrossRef
14.
Zurück zum Zitat Boer K, Darvas Z, Baki M, Kaszas I, Pal Z et al (2003) Expression of histidine decarboxylase in human colonic cancer cells and adenomatous polyps. Inflamm Res 52(Suppl 1):S76–S77PubMedCrossRef Boer K, Darvas Z, Baki M, Kaszas I, Pal Z et al (2003) Expression of histidine decarboxylase in human colonic cancer cells and adenomatous polyps. Inflamm Res 52(Suppl 1):S76–S77PubMedCrossRef
15.
Zurück zum Zitat Norrby K (1997) Mast cells and de novo angiogenesis: angiogenic capability of individual mast-cell mediators such as histamine, TNF, IL-8 and bFGF. Inflamm Res 46(Suppl 1):S7–S8PubMed Norrby K (1997) Mast cells and de novo angiogenesis: angiogenic capability of individual mast-cell mediators such as histamine, TNF, IL-8 and bFGF. Inflamm Res 46(Suppl 1):S7–S8PubMed
16.
Zurück zum Zitat Cui G, Waldum HL (2007) Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. World J Gastroenterol 13:493–496PubMed Cui G, Waldum HL (2007) Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. World J Gastroenterol 13:493–496PubMed
17.
Zurück zum Zitat Tippens AS, Gruetter CA (2004) Detection of histidine decarboxylase mRNA in human vascular smooth muscle and endothelial cells. Inflamm Res 53:215–216PubMedCrossRef Tippens AS, Gruetter CA (2004) Detection of histidine decarboxylase mRNA in human vascular smooth muscle and endothelial cells. Inflamm Res 53:215–216PubMedCrossRef
18.
Zurück zum Zitat El-Ackad TM, Brody MJ (1975) Evidence for non-mast cell histamine in the vascular wall. Blood Vessels 12:181–191PubMed El-Ackad TM, Brody MJ (1975) Evidence for non-mast cell histamine in the vascular wall. Blood Vessels 12:181–191PubMed
19.
Zurück zum Zitat Gruetter CA, Bailey B, Easterling L, Szarek JL (2002) Release of non-mast cell histamine from rat aorta. Life Sci 70:1709–1717PubMedCrossRef Gruetter CA, Bailey B, Easterling L, Szarek JL (2002) Release of non-mast cell histamine from rat aorta. Life Sci 70:1709–1717PubMedCrossRef
20.
Zurück zum Zitat Rhee J, Hoff PM (2005) Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 6:1701–1711PubMedCrossRef Rhee J, Hoff PM (2005) Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 6:1701–1711PubMedCrossRef
21.
Zurück zum Zitat Masini E, Fabbroni V, Giannini L, Vannacci A, Messerini L et al (2005) Histamine and histidine decarboxylase up-regulation in colorectal cancer: correlation with tumor stage. Inflamm Res 54(Suppl 1):S80–S81PubMedCrossRef Masini E, Fabbroni V, Giannini L, Vannacci A, Messerini L et al (2005) Histamine and histidine decarboxylase up-regulation in colorectal cancer: correlation with tumor stage. Inflamm Res 54(Suppl 1):S80–S81PubMedCrossRef
22.
Zurück zum Zitat Ai W, Takaishi S, Wang TC, Fleming JV (2006) Regulation of L-histidine decarboxylase and its role in carcinogenesis. Prog Nucleic Acid Res Mol Biol 81:231–270PubMedCrossRef Ai W, Takaishi S, Wang TC, Fleming JV (2006) Regulation of L-histidine decarboxylase and its role in carcinogenesis. Prog Nucleic Acid Res Mol Biol 81:231–270PubMedCrossRef
23.
Zurück zum Zitat Kuefner MA, Schwelberger HG, Hahn EG, Raithel M (2008) Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma. Dig Dis Sci 53:436–442PubMedCrossRef Kuefner MA, Schwelberger HG, Hahn EG, Raithel M (2008) Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma. Dig Dis Sci 53:436–442PubMedCrossRef
24.
Zurück zum Zitat Li Z, Liu J, Tang F, Liu Y, Waldum HL et al (2008) Expression of non-mast cell histidine decarboxylase in tumor-associated microvessels in human esophageal squamous cell carcinomas. APMIS 116:1034–1042PubMedCrossRef Li Z, Liu J, Tang F, Liu Y, Waldum HL et al (2008) Expression of non-mast cell histidine decarboxylase in tumor-associated microvessels in human esophageal squamous cell carcinomas. APMIS 116:1034–1042PubMedCrossRef
25.
Zurück zum Zitat Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef
26.
Zurück zum Zitat Yang JJ, Ma YL, Zhang P, Chen HQ, Liu ZH et al (2011) Histidine decarboxylase is identified as a potential biomarker of intestinal mucosal injury in patients with acute intestinal obstruction. Mol Med 17:1323–1337PubMedCrossRef Yang JJ, Ma YL, Zhang P, Chen HQ, Liu ZH et al (2011) Histidine decarboxylase is identified as a potential biomarker of intestinal mucosal injury in patients with acute intestinal obstruction. Mol Med 17:1323–1337PubMedCrossRef
28.
Zurück zum Zitat Ghosh AK, Hirasawa N, Ohtsu H, Watanabe T, Ohuchi K (2002) Defective angiogenesis in the inflammatory granulation tissue in histidine decarboxylase-deficient mice but not in mast cell-deficient mice. J Exp Med 195:973–982PubMedCrossRef Ghosh AK, Hirasawa N, Ohtsu H, Watanabe T, Ohuchi K (2002) Defective angiogenesis in the inflammatory granulation tissue in histidine decarboxylase-deficient mice but not in mast cell-deficient mice. J Exp Med 195:973–982PubMedCrossRef
29.
Zurück zum Zitat Ghosh AK, Hirasawa N, Ohuchi K (2001) Enhancement by histamine of vascular endothelial growth factor production in granulation tissue via H(2) receptors. Br J Pharmacol 134:1419–1428PubMedCrossRef Ghosh AK, Hirasawa N, Ohuchi K (2001) Enhancement by histamine of vascular endothelial growth factor production in granulation tissue via H(2) receptors. Br J Pharmacol 134:1419–1428PubMedCrossRef
30.
Zurück zum Zitat Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L et al (2005) The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 11:6807–6815PubMedCrossRef Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L et al (2005) The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 11:6807–6815PubMedCrossRef
31.
Zurück zum Zitat Hellstrand K, Brune M, Naredi P, Mellqvist UH, Hansson M et al (2000) Histamine: a novel approach to cancer immunotherapy. Cancer Investig 18:347–355CrossRef Hellstrand K, Brune M, Naredi P, Mellqvist UH, Hansson M et al (2000) Histamine: a novel approach to cancer immunotherapy. Cancer Investig 18:347–355CrossRef
Metadaten
Titel
The Expression of Non-Mast Histamine in Tumor Associated Microvessels in Human Colorectal Cancers
verfasst von
Jing Cui
Gang Xu
Jinzhong Liu
Zhigang Pang
Jon Florholmen
Guanglin Cui
Publikationsdatum
01.04.2013
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2013
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-012-9584-y

Weitere Artikel der Ausgabe 2/2013

Pathology & Oncology Research 2/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.